Clinical Trials Recruiting near Minneapolis, MN
942 clinical trials have a recruiting site within 25 miles of Minneapolis, Minnesota, according to ClinicalTrials.gov data processed . The closest recruiting site is within 1 mile of the city center.
Distances are measured from the city center to each site's city, so they are approximate.
Recruiting now
Studies enrolling near Minneapolis
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149
- Phase 2
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 21 sites within 25 mi
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
- Phase 2/3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 21 sites within 25 mi
- A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
- Interventional
- Ages 35 to 50 years
- Sex: Female
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 21 sites within 25 mi
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 21 sites within 25 mi
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
- Phase 2
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 20 sites within 25 mi
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 20 sites within 25 mi
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
- Phase 3
- Ages 18 years and older
- Sex: Male
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 20 sites within 25 mi
- Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
NCT04871542
- Observational
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 20 sites within 25 mi
- Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673
- Interventional
- Ages 45 to 70 years
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 20 sites within 25 mi
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 20 sites within 25 mi
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
- Phase 2
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
NCT05008848
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
- Phase 2/3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
- Observational
- Ages 40 to 75 years
- Sex: All
- Accepts healthy volunteers
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
- Phase 3
- Ages 18 to 60 years
- Sex: Female
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Family Communications After Genetic Testing
NCT07143487
- Interventional
- Ages 18 years and older
- Sex: All
- Accepts healthy volunteers
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939
- Interventional
- Ages 18 years and older
- Sex: All
- Accepts healthy volunteers
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 19 sites within 25 mi
- S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
- Interventional
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 17 sites within 25 mi
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 17 sites within 25 mi
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013
- Phase 2
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 17 sites within 25 mi
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
- Phase 2
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 16 sites within 25 mi
- Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095
- Observational
- Ages Any age
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 16 sites within 25 mi
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360
- Phase 2
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 16 sites within 25 mi
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
- Phase 3
- Ages Any age
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 16 sites within 25 mi
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 16 sites within 25 mi
- Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243
- Phase 3
- Ages 18 years and older
- Sex: Male
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 16 sites within 25 mi
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377
- Phase 3
- Ages 18 years and older
- Sex: All
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 15 sites within 25 mi
By condition
Clinical trials in Minneapolis by condition
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.